Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR
Anergis announced that it received a notice of allowance from the US patent authorities for its patent covering composition and methods of use of its ragweed allergy product AllerR. AllerR is based on Anergis´ unique Contiguous Overlapping Peptide (COP) platform. COPs are pharmaceutical-grade, long-peptide immunotherapeutics designed for an ultra-fast, safe and long-lasting treatment of allergy patients.
Ragweed pollen is believed to be the most allergenic of all pollens. Allergies to ragweed pollen are mostly prevalent in the USA, where they affect an estimated 27 million patients, with a high degree of severity in many of them. Among others, ragweed allergies are a major cause of asthma. Fifty percent (50%) of allergic patients in the United States are sensitized to ragweed.
"Allowance of the patent on AllerR in the U.S. is a major milestone in broadening our international patent estate," said Christophe Reymond, Chief Scientific Officer of Anergis.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Sartorius International Biosciences Scholarship: Technology group sets up international scholarship program

Merck Completes € 180 Million Investment to Expand Schnelldorf Distribution Center
Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety
Category:Smallpox

May repairs full of mistakes develop into cancer?
ITI Life Sciences Seeks to Fund Innovative Drug Discovery Programme based on Ubiquitin

Natural UV radiation in winter not strong enough against SARS-CoV-2 - In winter the virus has a good chance of survival outside
Intermittent hormone therapy for prostate cancer inferior to continuous therapy
EMBO awards Installation Grants to seven talented European researchers
Category:Aminoglycoside_antibiotics
